ANN ARBOR, MI / ACCESSWIRE / May 6, 2020 / ENDRA Life Sciences Inc. (''ENDRA'') (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS™), has recently been issued design patents D883487 and D883488 from the United States Patent and Trademark Office for its "Thermoacoustic Imaging Probe" and "Thermoacoustic Imaging Probe With Outdents".

"ENDRA's goal is to develop applications for our proprietary TAEUS technology in areas of high unmet clinical need, such as Non-Alcoholic Fatty Liver Disease (NAFLD) which affects over 1 billion people globally, and for which there are no practical diagnostic tools. The recently-issued ‘487 and 488' patents provide more robust intellectual property (IP) protection for our TAEUS platform in a key global market. In particular, the ‘487 patent protects the basic appearance of the FLIP probe, including the relevant combination of shapes and surface markings, while the ‘488 patent protects a user-friendly embodiment of the ‘487 patent," explained ENDRA's Chief Executive Officer, Francois Michelon. "Our IP portfolio continues to grow and currently stands at 68 defined, filed, issued, and/or licensed assets, which will provide significant market protection as we enter the commercialization phase for our technology."

About ENDRA Life Sciences Inc.

ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS™), a ground-breaking technology that visualizes tissue like CT or MRI, but at 50X lower cost, at the point of patient care. TAEUS is designed to work in concert with one million ultrasound systems in global use today. TAEUS is initially focused on the measurement of fat in the liver, as a means to assess and monitor NAFLD and NASH, chronic liver conditions that affect over 1 billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures. www.endrainc.com

Forward-Looking Statements

All statements in this release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "goal," "estimate," "anticipate" or other comparable terms. Examples of forward-looking statements include, among others, statements we make regarding the results of human studies and the nature of data obtained from such studies; expectations concerning the anticipated design and timing of future clinical studies; estimates of the timing of future events and achievements, including obtaining regulatory approvals and commercializing the TAEUS device; and expectations concerning ENDRA's business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including, among others, the following: our ability to develop a commercially feasible technology; receipt of necessary regulatory approvals; our ability to find and maintain development partners, market acceptance of our technology, the amount and nature of competition in our industry; our ability to protect our intellectual property; and the other risks and uncertainties described in ENDRA's filings with the Securities and Exchange Commission. The forward-looking statements made in this release speak only as of the date of this release, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.

Company Contact:

David Wells
Chief Financial Officer
(734) 997-0464
investors@endrainc.com
www.endrainc.com

Media Relations Contact:

Denise DiMeglio
(610) 228-2102
denise@gregoryfca.com

Investor Relations Contact:

Joe Hassett
(484) 686-6600
joeh@gregoryfca.com

SOURCE: ENDRA Life Sciences Inc.



View source version on accesswire.com:
https://www.accesswire.com/588630/ENDRA-Life-Sciences-Strengthens-IP-Portfolio-with-Issuance-of-Additional-Patents-for-its-Innovative-Fatty-Liver-Imaging-Probe